Evidence-based outcomes for patients with advanced non-small cell lung cancer

Seminars in Respiratory and Critical Care Medicine

Volumn 21, Issue 5, 2000, Pages 443-449

  Reif, M S ^a   Rivera, M P ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Advanced stage; Chemotherapy; Non small cell lung cancer

Indexed keywords

CARBOPLATIN; CISPLATIN; ETOPOSIDE; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; NAVELBINE; PACLITAXEL; TENIPOSIDE; VINDESINE;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; EVIDENCE BASED MEDICINE; HUMAN; LUNG NON SMALL CELL CANCER; META ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; REVIEW; TREATMENT OUTCOME;

EID: 0033809246     PISSN: 10693424     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2000-9405     Document Type: Review

References (39)

1. Perceptions of prognosis, treatment, and treatment impact on prognosis in non-small cell lung cancer
2. Cancer Statistics
3. Cisplatin-cyclophosphamide-mitomycin combination chemotherapy with supportive care versus supportive care alone for treatment of metastatic non-small-cell lung cancer
4. A randomized trial of alternating chemotherapy versus best supportive care in advanced non-small-cell lung cancer
5. Benefits of polychemotherapy in advanced non-small-cell bronchogenic carcinoma
6. Supportive care versus supportive care and combination chemotherapy in metastatic non-small cell lung cancer. Does chemotherapy make a difference?
7. Quality of life and survival in patients with advanced non-small cell lung cancer receiving supportive care plus chemotherapy with carboplatin and etoposide or supportive care only. A multi-centre randomised Phase III trial. Joint Lung Cancer Study Group
8. Symptomatic treatment versus combination chemotherapy for patients with extensive non-small cell lung cancer
9. Is chemotherapy with cisplatin useful in non small cell bronchial cancer at staging IV? Results of a randomized study
10. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer-report of a Canadian multicenter randomized trial
11. Relationship between quality of life and clinical outcomes in advanced non-small cell lung cancer: Best supportive care (BSC) versus BSC plus chemotherapy
12. A randomised trial of cisplatin and vindesine versus supportive care only in advanced non-small cell lung cancer
13. Frquency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small-cell lung cancer treated with combination chemotherapy
14. Survival determinants in extensive-stage non-small-cell lung cancer: The Southwest Oncology Group experience
15. Chemotherapy for metastatic non-small-cell bronchogenic carcinoma: EST 2575, generation V - A randomized comparison of four cisplatin-containing regimens
16. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials
17. Chemotherapy vs supportive care in advanced non-small-cell lung cancer. Results of a meta-analysis of the literature
18. Meta-analysis of randomised trials of systemic chemotherapy versus supportive treatment in non-resectable non-small cell lung cancer
19. Chemotherapy for advanced non-small-cell lung cancer: How much benefit is enough?
20. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: Results of a European multicenter trial including 612 patients
21. Randomized phase III study of gemcitabine-cisplatin versus etoposidecisplatin in the treatment of locally advanced or metaststic non-small-cell lung cancer
22. Final results of an EORTC phase III study of paclitaxel versus teniposide, in combination with cisplatin, in advanced NSCLC
23. Randomized phase III trial comparing cisplatin/etoposide versus carboplatin/paclitaxel in advanced and metastatic non-small cell lung (NSCLC)
24. Phase III trial comparing etoposide (E), cisplatin (C) versus Taxol (T) with cisplatin-G-CSF (G) versus taxol-cisplatin in advanced non-small cell lung cancer. An Eastern Cooperative Group (ECOG) trial
25. Phase III comparative study of high-dose cisplatin (HD-CIS) versus a combination of paclitaxel (TAX) and cisplatin (CIS) in patients with advanced non-small-cell lung cancer (NSCLC)
26. A Randomized Phase III Trial of Paclitaxel Plus Carboplatin (PC) Versus Vinorelbine Plus Cisplatin (VC) in Untreated Advanced Non-Small Cell Lung Cancer (NSCLC): A Southwest Oncology Group (SWOG) Trial
27. Phase III study of cisplatin (C) with or without gemcitabine (G) in patients with advanced non-small cell lung cancer (NSCLC)
28. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: A Southwest Oncology Group study
29. Cisplatin, gemcitabine, and vinorelbine combination therapy in advanced non-small-cell lung cancer: A Phase II randomized study of the Southern Italy Cooperative Oncology Group
30. Cisplatin-gemcitabinevinorelbine vs cisplatin-vinorelbine in advanced non-small-cell lung cancer: Interim analysis of a SICOG phase III trial
31. Inoperable non-small-cell lung cancer (NSCLC) A Medical Research Council randomised trial of palliative radiotherapy with two fractions or ten fractions. Report to the Medical Research Council by its Lung Cancer Working Party
32. Hypofractionated radiation therapy for inoperable advanced stage non-small cell lung cancer
33. New therapeutic strategies involving radiation therapy for patients with non-small cell lung cancer
34. Quality of life during chemotherapy in non-small cell lung cancer patients
35. Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer
36. Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial in nonsmall-cell lung cancer
37. Economic evaluation of a randomized clinical trial comparing vinorelbine, vinorelbine plus cisplatin, and vindesine plus cisplatin for non-small-cell lung cancer
38. A comparison of the costs of paclitaxel and best supportive care in stage IV non-small-cell lung cancer
39. The cost-effectiveness of navelbine alone or in combination with cisplatin in comparison to other chemotherapy regimens and best supportive care in stage IV non-small cell lung cancer